ArticleESMO open2026

Corrigendum to 'Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies': [ESMO Open Volume 11, Issue 7, July 2026, 107706].

J W Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.